Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections

Overview

Hypothesis: A short course (3-5 days) of antibiotic therapy (experimental arm) is as safe and effective as a long course of antibiotic therapy for the treatment of catheter-associated urinary tract infections.

Full Title of Study: “Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2017

Interventions

  • Other: Short-course Antibiotics
    • 3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
  • Device: Catheter Change
    • Urinary catheter change once randomization is complete.

Arms, Groups and Cohorts

  • No Intervention: Control
    • Subject receives the standard of care that is provided by the primary team taking up his/her case.
  • Experimental: Catheter change+Short-course Antibiotics

Clinical Trial Outcome Measures

Primary Measures

  • Resolution
    • Time Frame: Day 14 post-randomisation
    • Resolution of signs and symptoms of CAUTI

Secondary Measures

  • Short-Term Resolution
    • Time Frame: day 3 and day 7 post-randomisation
    • Resolution of signs and symptoms of CAUTI
  • Recurrence of fever or symptoms
    • Time Frame: 7, 14 and 30 days post randomization
  • Haemodynamic instability
    • Time Frame: day 14 post randomization
  • Admission to high dependency or intensive care units
    • Time Frame: 14 days post-randomization
  • Length of hospitalization
    • Time Frame: 30 days post-randomization
  • Re-admission
    • Time Frame: Day 30 post-randomization
  • Secondary Infections
    • Time Frame: 3 months post-randomization
  • Recurrent Urinary Tract Infections
    • Time Frame: 3 months and 1 year post-randomization
  • Urologic surgery or procedure
    • Time Frame: 1 year post-randomization
  • Antimicrobial use and duration
    • Time Frame: 1 month post-randomization
  • Colonization or infection by antibiotic-resistant organisms
    • Time Frame: 30 days post-randomization

Participating in This Clinical Trial

Inclusion Criteria

1. Inpatients ≥ 21 years old. 2. Presence of indwelling urinary catheter at the time of urine culture for ≥2days. 3. Fever >38°C. 4. A urine specimen sent to the hospital microbiological laboratory for culture. 5. An antibiotic order for presumed symptomatic catheter associated urinary tract infection. Exclusion Criteria:

1. Persistent fever >38°C for more than 24 hours, or any fever >38.9°C. 2. Haemodynamic instability, defined as:

  • Requirement for intravenous vasopressor agents – Systolic blood pressure <90 mmHg – Acute hypotensive event with drop in systolic blood pressure of >30 mmHg or diastolic blood pressure of >20 mmHg 3. The following laboratory values within the previous 48 hours (if available): – White blood cell count>15 or <4 x10^9/L. – Procalcitonin>0.25ug/mL – C Reactive Protein >100mg/mL – An increase in the serum creatinine of more than 50% from baseline 4. New requirement for oxygen supplement. 5. Current admission to a high dependency unit or ICU. 6. Radiological evidence of an upper urinary tract infection 7. Flank pain or tenderness, suggesting an upper urinary tract infection 8. Urologic surgical procedure within the previous 72 hours 9. Known structural genitourinary abnormalities including: – Nephrostomy tubes – Tumours of the urinary tract – Ureteric stenting – Ureteric strictures – Urolithiasis 10. Bloodstream or other significant infection suspected at any site other than the catheterized urinary tract. 11. Received antibiotics for more than 48 hours prior to randomization. 12. Positive urinary culture with organism resistant to all the investigational antibiotics in the week prior to randomisation. 13. Hypersensitivity to ciprofloxacin, cotrimoxazole and amoxicillin-clavulanate. 14. Pregnancy.

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National University Hospital, Singapore
  • Collaborator
    • Tan Tock Seng Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Paul A Tambyah, MD, Principal Investigator, National University Hospital, Singapore
  • Overall Contact(s)
    • Paul A Tambyah, MD, paul_anantharajah_tambyah@nuhs.edu.sg

References

Edwards JR, Peterson KD, Andrus ML, Tolson JS, Goulding JS, Dudeck MA, Mincey RB, Pollock DA, Horan TC; NHSN Facilities. National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007. Am J Infect Control. 2007 Jun;35(5):290-301. doi: 10.1016/j.ajic.2007.04.001. No abstract available.

Schaberg DR, Weinstein RA, Stamm WE. Epidemics of nosocomial urinary tract infection caused by multiply resistant gram-negative bacilli: epidemiology and control. J Infect Dis. 1976 Mar;133(3):363-6. doi: 10.1093/infdis/133.3.363. No abstract available.

Milan PB, Ivan IM. Catheter-associated and nosocomial urinary tract infections: antibiotic resistance and influence on commonly used antimicrobial therapy. Int Urol Nephrol. 2009;41(3):461-4. doi: 10.1007/s11255-008-9468-y. Epub 2008 Sep 12.

Tambyah PA, Knasinski V, Maki DG. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. Infect Control Hosp Epidemiol. 2002 Jan;23(1):27-31. doi: 10.1086/501964.

Wald HL, Ma A, Bratzler DW, Kramer AM. Indwelling urinary catheter use in the postoperative period: analysis of the national surgical infection prevention project data. Arch Surg. 2008 Jun;143(6):551-7. doi: 10.1001/archsurg.143.6.551.

Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010 Mar 1;50(5):625-63. doi: 10.1086/650482.

Ng E, Earnest A, Lye DC, Ling ML, Ding Y, Hsu LY. The excess financial burden of multidrug resistance in severe gram-negative infections in Singaporean hospitals. Ann Acad Med Singap. 2012 May;41(5):189-93.

Harding GK, Nicolle LE, Ronald AR, Preiksaitis JK, Forward KR, Low DE, Cheang M. How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study. Ann Intern Med. 1991 May 1;114(9):713-9. doi: 10.7326/0003-4819-114-9-713.

Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008 Jan;71(1):17-22. doi: 10.1016/j.urology.2007.09.002.

Dow G, Rao P, Harding G, Brunka J, Kennedy J, Alfa M, Nicolle LE. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis. 2004 Sep 1;39(5):658-64. doi: 10.1086/423000. Epub 2004 Aug 13.

Raz R, Schiller D, Nicolle LE. Chronic indwelling catheter replacement before antimicrobial therapy for symptomatic urinary tract infection. J Urol. 2000 Oct;164(4):1254-8.

Darouiche RO, Al Mohajer M, Siddiq DM, Minard CG. Short versus long course of antibiotics for catheter-associated urinary tract infections in patients with spinal cord injury: a randomized controlled noninferiority trial. Arch Phys Med Rehabil. 2014 Feb;95(2):290-6. doi: 10.1016/j.apmr.2013.09.003. Epub 2013 Sep 11.

Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):505-11. doi: 10.1164/ajrccm.162.2.9909095.

Hamasuna R, Takahashi S, Yamamoto S, Arakawa S, Yanaihara H, Ishikawa S, Matsumoto T. Guideline for the prevention of health care-associated infection in urological practice in Japan. Int J Urol. 2011 Jul;18(7):495-502. doi: 10.1111/j.1442-2042.2011.02769.x. Epub 2011 May 16.

Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med. 2000 Mar 13;160(5):678-82. doi: 10.1001/archinte.160.5.678.

Corey GR, Stryjewski ME. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Clin Infect Dis. 2011 Jun;52 Suppl 7:S469-76. doi: 10.1093/cid/cir162.

Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials. 1982 Dec;3(4):345-53. doi: 10.1016/0197-2456(82)90024-1.

Scott IA. Non-inferiority trials: determining whether alternative treatments are good enough. Med J Aust. 2009 Mar 16;190(6):326-30. doi: 10.5694/j.1326-5377.2009.tb02425.x.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.